Related references
Note: Only part of the references are listed.Interim Report of A Phase 2 Clinical Trial of Lenalidomide for T-Cell Non-Hodgkin Lymphoma
Greg Dueck et al.
CANCER (2010)
Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
A. K. Gandhi et al.
CURRENT CANCER DRUG TARGETS (2010)
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
Carla Heise et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
Taimur Sher et al.
LEUKEMIA & LYMPHOMA (2010)
Management of Patients With Chronic Lymphocytic Leukemia Treated With Lenalidomide
Kena C. Miller et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2010)
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Thomas M. Habermann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Christine Galustian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
Sharon L. Sanborn et al.
INVESTIGATIONAL NEW DRUGS (2009)
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Thomas E. Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer
William L. Dahut et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2009)
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Alessandra Ferrajoli et al.
BLOOD (2008)
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Lei Wu et al.
CLINICAL CANCER RESEARCH (2008)
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Peter H. Wiernik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
David H. Chang et al.
BLOOD (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
K Dredge et al.
MICROVASCULAR RESEARCH (2005)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
D Gupta et al.
LEUKEMIA (2001)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Share Paper
